Pyrazinamide monoresistance in clinical isolates
| dc.contributor.author | Kalir, N | |
| dc.contributor.author | Özkütük, AA | |
| dc.contributor.author | Esen, N | |
| dc.contributor.author | Özkütük, N | |
| dc.date.accessioned | 2024-07-18T12:03:01Z | |
| dc.date.available | 2024-07-18T12:03:01Z | |
| dc.description.abstract | Aim: To determine pyrazinamide (PZA) monoresistance in clinical isolates of Mycobacterium tuberculosis complex (MTBC) isolated in hospitals in and around Izmir. Materials and methods: The study was performed between 2004 and 2009 with 150 streptomycin, isoniazid, rifampicin, and ethambutol susceptible MTBC clinical strains isolated in the university hospitals of Izmir and Manisa. The PZA susceptibility of the isolates was determined by the BACTEC 460 TB test. Results: The results indicated that resistance to PZA was present in 5 (3.3%) of the 150 MTBC isolates susceptible to all primary drugs except PZA. Conclusion: It is not essential to perform PZA susceptibility tests routinely along with other primary drugs due to the low PZA monoresistance level in our region. | |
| dc.identifier.issn | 1300-0144 | |
| dc.identifier.other | 1303-6165 | |
| dc.identifier.uri | http://akademikarsiv.cbu.edu.tr:4000/handle/123456789/8846 | |
| dc.language.iso | English | |
| dc.publisher | Tubitak Scientific & Technological Research Council Turkey | |
| dc.subject | RESISTANT MYCOBACTERIUM-TUBERCULOSIS | |
| dc.subject | DRUG-RESISTANCE | |
| dc.subject | PNCA MUTATIONS | |
| dc.subject | SUSCEPTIBILITY | |
| dc.subject | REGION | |
| dc.title | Pyrazinamide monoresistance in clinical isolates | |
| dc.type | Article |